Bristol Myers Squibb stock gains on Zenbexus approval

Bristol Myers Squibb stock gained after the FDA approved Zenbexus in multiple myeloma on August 13, 2026, while the shares closed at $66.07 on August 18, 2026. The stock also changed hands at $66.15 in extended trading that evening, with a market cap of $132.18 billion.

Approval gives the rally a second leg

The approval covers Zenbexus, also known as iberdomide, in combination with daratumumab and dexamethasone for adults with multiple myeloma who have already had at least one prior line of therapy. That matters because the FDA decision adds a fresh commercial catalyst to a stock that already trades on a low-teens valuation in market-portal data.

On the same trading snapshot, the share price was up 2.23% to $66.07, and the move came alongside a consensus price target of $66.06. That leaves the stock priced almost exactly in line with the average twelve-month view that has been published for the name.

Latest quarter still sets the tone

Market data services that cite the latest company period show Bristol Myers Squibb reported second-quarter 2026 revenue of $12.97 billion and EPS of $1.62, against estimates of $11.75 billion and $1.59. Revenue was therefore $1.22 billion ahead of the estimate, a concrete beat that helps explain why investors still treat the company as a cash-generating large-cap pharma name.

Those figures also matter because the stock is not just reacting to one regulatory win. A company that can pair a second-quarter 2026 revenue beat with a new FDA-approved therapy has a clearer near-term narrative than one relying on pipeline optionality alone.

What Zenbexus adds

Zenbexus is the new commercial hook inside the portfolio, and the approval places another blood-cancer medicine in the market mix. That gives investors a product-specific catalyst to weigh against the broader earnings base, rather than a purely theoretical pipeline story.

The key question now is whether uptake can build fast enough to make the approval visible in later quarterly numbers. With the shares already close to the average target, the market is asking for proof in the data, not just the headline.

Shares near fair value

As of August 18, 2026, Bristol Myers Squibb was trading at $66.07 with a market cap of $132.18 billion. Extended trading showed $66.15 that night, keeping the stock close to the center of its current analyst range.